AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
Data published in July 7, 2009 Issue of Proceedings of the National Academy of Sciences
The data show that mice treated with ghrelin increase their alcohol consumption. When ghrelin’s actions are blocked by administering ghrelin receptor antagonists such as AEZS-123, mice no longer show preference for an alcohol-associated environment – in other words, alcohol is no longer able to produce its addictive effects that include reward searching behaviour (akin to craving in alcoholic patients).
The work, coordinated by AEterna Zentaris, emerged from an international collaboration between the research groups of Prof.
Daniel Perrissoud, Senior Director of Project Management at AEterna Zentaris and one of the authors of the paper stated, “The discovery of the
The article entitled, “Requirement of Central Ghrelin Signaling for Alcohol Reward” appears today in the
About AEterna Zentaris’ Ghrelin Antagonist Program
Ghrelin is a natural peptide hormone produced by the stomach that increases appetite and induces accumulation of fat tissue. The discovery of ghrelin and its receptors opens up new opportunities for the treatment of obesity and eating disorders through the use of ghrelin antagonists to suppress appetite and fat deposition.
In 2004, AEterna Zentaris signed two agreements for the development of ghrelin antagonists with the Institut des biomolecules Max Mousseron of the University of Montpellier,
In 2006, AEterna Zentaris reported first in vivo pharmacological data on the capability of proprietary ghrelin receptor antagonists to selectively inhibit food intake.
At the annual meetings of the American Endocrine Society (ENDO) of 2007 and 2008, Prof.
About the Food and Alcohol Addiction Market
There is no safe and effective appetite suppressant currently on the market. It is estimated that between 34 million and 61 million Americans are obese, and the worldwide incidence of obesity is increasing by an estimated 1% per year.
Alcohol dependence is a complex and chronic disease which leads to adverse consequences affecting not only the patients but also their immediate family and has a profound economic burden on society. The annual costs to
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.
SOURCE AETERNA ZENTARIS INC.